ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO195

Changes in Serum Phosphorus (sP) Among Patients with Hyperphosphatemia (sP >5.5 mg/dL) Switched to Sucroferric Oxyhydroxide for Two Years

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Sprague, Stuart M., NorthShore University HealthSystem University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
  • Parameswaran, Vidhya, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Ficociello, Linda, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Mullon, Claudy, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Kossmann, Robert J., Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
Background

Hemodialysis (HD) patients are advised to keep sP levels ≤ 5.5 mg/dl through diet modification and use of phosphate binders (PB). Sucroferric oxyhydroxide (SO) has been prescribed to hemodialysis patients for the control of sP as part of routine clinical care. This database analysis retrospectively analyzed sP and PB pill burden in patients who had a mean sP level > 5.5 mg/dl at baseline and were prescribed SO for up to two years.

Methods

The analysis included adult HD patients with sP > 5.5 mg/dl at baseline (3-month, -Q1) who were switched to SO as part of routine care for up to two years (Q1-Q8). Patients were stratified into 3 groups based on baseline sP: Group 1: sP 5.6-7 mg/dl, Group 2: sP 7.1-8.5 mg/dl, and Group 3: sP >8.5 mg/dl. Mixed effects linear regression was used for significance testing.

Results

There were 2067, 1381, and 479 patients in Groups 1, 2, and 3, respectively. 84% had recorded PB prescriptions at baseline with the majority prescribed sevelamer. Table 1 shows the percent of patients who achieved sP ≤5.5 mg/dl and mean sP levels by group. In Groups 1 and 2, 42% and 22% of patients had sP ≤5.5 mg/dl after 2 years of follow-up. In the group with the highest baseline sP level, Group 3, sP ≤ 5.5 mg/d was achieved in 8.3% of patients, and the mean sP for this group decreased from 9.36 mg/dl to 7.62 at Q8, a 19% reduction in sP (-1.74 mg/dl). On average, the PB pill burden was reduced in groups 1, 2, and 3 from 8.7, 9.7, and 9.9 PB pills/day at baseline to 4.9, 5.3 and 5.4 SO pills/day at Q8, respectively.

Conclusion

Patients with elevated sP levels at baseline switched to sucroferric oxyhydroxide for up to two years as part of routine care, experienced significant reductions in sP along with a >40% reduction in PB pills/day and increase in patients with sP ≤5.5 mg/dl.

Funding

  • Commercial Support